Bristol Myers (NYSE: BMY) shares Q4 and full-year 2025 update

Rhea-AI Filing Summary

Bristol-Myers Squibb Company furnished an update on its recent performance by issuing an earnings press release and investor presentation covering financial results for the fourth quarter of 2025 and the full year 2025.

The company posted the earnings press release and a “Bristol Myers Presentation” on its website in connection with an earnings conference call and webcast. Both materials include non-GAAP financial measures, with reconciliations and explanations provided in the press release. These materials are furnished, not filed, under the Exchange Act and are not automatically incorporated into future SEC filings.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0000014272false00000142722026-02-052026-02-050000014272bmy:CommonStock0.10ParValueMember2026-02-052026-02-050000014272bmy:CelgeneContingentValueRightsMember2026-02-052026-02-050000014272bmy:A2.973NotesDue2030Member2026-02-052026-02-050000014272bmy:A3.363NotesDue2033Member2026-02-052026-02-050000014272bmy:A1.750Notesdue2035Member2026-02-052026-02-050000014272bmy:A3.857NotesDue2038Member2026-02-052026-02-050000014272bmy:A4.289NotesDue2045Member2026-02-052026-02-050000014272bmy:A4.581NotesDue2055Member2026-02-052026-02-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________

FORM 8-K

_____________________________

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 5, 2026

_____________________________

BRISTOL-MYERS SQUIBB COMPANY

(Exact name of registrant as specified in its charter)

_____________________________

Delaware			001-01136			22-0790350
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(I.R.S Employer Identification No.)

Route 206 & Province Line Road, Princeton, New Jersey 08543

(Address of principal executive offices) (Zip Code)

(Registrant’s telephone number, including area code): (609) 252-4621

_____________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.10 Par Value			BMY			New York Stock Exchange
Celgene Contingent Value Rights			CELG RT			New York Stock Exchange
2.973% Notes due 2030			BMY/30			New York Stock Exchange
3.363% Notes due 2033			BMY/33			New York Stock Exchange
1.750% Notes due 2035			BMY/35			New York Stock Exchange
3.857% Notes due 2038			BMY/38			New York Stock Exchange
4.289% Notes due 2045			BMY/45			New York Stock Exchange
4.581% Notes due 2055			BMY/55			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On February 5, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the fourth quarter of 2025 and full year of 2025. A copy of the Earnings Press Release is furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. Other than the Earnings Press Release, the information contained in or connected to the Company's website is not deemed to be incorporated by reference in this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

On February 5, 2026, the Company posted on its website at www.bms.com a presentation (the “Bristol Myers Presentation”) on certain financial and operating initiatives available for viewing during the Company’s conference call and webcast announcing its financial results for the fourth quarter of 2025 and full year of 2025 at 8:00 a.m. Eastern time. A copy of the Bristol Myers Presentation is furnished pursuant to this Item 7.01 as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. The Earnings Press Release and the Bristol Myers Presentation include references to non-GAAP financial information. Reconciliations between the non-GAAP financial measures and the comparable GAAP financial measures and the reasons for the presentation of such non-GAAP financial measures, are available in the Earnings Press Release which is included as Exhibit 99.1 hereto. The Bristol Myers Presentation should be read in conjunction with the Earnings Press Release. The Company reserves the right to discontinue availability of the Bristol Myers Presentation from its website at any time.

Pursuant to General Instruction B.2. to Form 8-K, the information set forth in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by the Company under the Exchange Act or under the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing. Additionally, the submission of the information set forth in this Item 7.01 is not deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely by Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are furnished as part of this Current Report on Form 8-K:

Exhibit No.						Description
99.1						Press release of Bristol-Myers Squibb Company dated February 5, 2026
99.2						Presentation Materials of Bristol-Myers Squibb Company dated February 5, 2026
104						The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

BRISTOL-MYERS SQUIBB COMPANY

Dated: February 5, 2026

By:

/s/ Amy Fallone

Name:

Amy Fallone

Title:

Corporate Secretary

FAQ

What did Bristol-Myers Squibb (BMY) disclose in this 8-K filing?

Bristol-Myers Squibb furnished an earnings press release and an investor presentation covering its fourth-quarter 2025 and full-year 2025 financial results, making them available on its website and attaching them as Exhibits 99.1 and 99.2.

Which periods do Bristol-Myers Squibb’s latest results cover in this 8-K?

The materials furnished with this 8-K present Bristol-Myers Squibb’s financial results for the fourth quarter of 2025 and the full year of 2025, supporting an earnings conference call and webcast held on February 5, 2026.

How does Bristol-Myers Squibb use non-GAAP measures in its Q4 and 2025 results?

The earnings press release and Bristol Myers Presentation include non-GAAP financial measures, with reconciliations to comparable GAAP figures and explanations for their use provided within the press release, which is attached as Exhibit 99.1.

Are the Bristol-Myers Squibb exhibits in this 8-K considered filed with the SEC?

The company states that the information in Item 7.01, including Exhibits 99.1 and 99.2, is furnished rather than filed under the Exchange Act and is not subject to Section 18 liabilities or automatically incorporated into future filings.

Where can investors access Bristol-Myers Squibb’s Q4 2025 earnings materials?

Bristol-Myers Squibb posted the earnings press release and Bristol Myers Presentation on its website at www.bms.com, and also furnished them as Exhibits 99.1 and 99.2 to the 8-K for reference alongside the company’s conference call.

What exhibits are included with Bristol-Myers Squibb’s February 5, 2026 8-K?

The filing includes three exhibits: a February 5, 2026 press release as Exhibit 99.1, presentation materials as Exhibit 99.2, and the Inline XBRL-formatted cover page as Exhibit 104, all tied to the company’s Q4 and full-year 2025 results.